GSK officials to meet with Irish union; Suit accuses Wyeth of illegal patents;

@FiercePharma: Bayer joins social media follies with tweet apology. Piece | Follow @FiercePharma

> Management at a GlaxoSmithKline operation in Ireland are meeting with union representatives who seek a commitment that there will be no compulsory redundancies as the company seeks to shave 130 jobs from its workforce there. News

> A federal lawsuit filed in Mississippi claims that Wyeth made millions of dollars by misrepresenting clinical data and using sham litigation to maintain a monopoly over its antidepressant drug Effexor XR. Item

> ProStrakan, the Scotland-based specialty pharma that is now a subsidiary of Japan's Kyowa Hakko Kirin, said Dr. Tom Stratford, the son of the company's co-founder, has been appointed as its new chief executive. Report

> Artificial hip joints made by Johnson & Johnson have plaintiffs' attorneys flocking to the courthouse. Story

> Drugmaker Cadila Healthcare plans to raise at least 1.5 billion rupees via 5 year bonds through bookbuilding, two sources with knowledge of the deal told Reuters. Piece

> India's Wockhardt got tentative approval from FDA to market its version of the Eli Lilly antidepressant Cymbalta. Article

Biotech News

@FierceBiotech: Innate shares soar on record $465M antibody pact with BMS. News | Follow @FierceBiotech

@JohnCFierce: I'm still wondering if developers have turned a corner, or if this is just a lucky streak. How would you vote? | Follow @JohnCFierce

> Woodcock: New drug approvals reach 20-year high. Article

> Long-awaited biotech IPOs on horizon in land of Novartis and Roche? Report

> Amylin shares jump on upbeat heart rate study with diabetes drug. Story

> Merck KGaA nixes development of Idera Pharma cancer drug. Item

And Finally... When poor people are given medical insurance, they not only find regular doctors and see them more often but they also feel better, are less depressed and are better able to maintain financial stability, according to a study. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.